Get started
Author

Ezgi B Ulas

Association of Machine Learning–Based Assessment of Tumor-Infiltrating Lymphocytes on Standard Histologic Images With Outcomes of Immunotherapy in Patients With NSCLC
2022 · Mehrdad Rakaee, Elio Adib, et al. · JAMA Oncology · 142
Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review
2021 · E.B. Ulas, C. Dickhoff, et al. · ESMO Open · 72
Predictive Value of Combined Positive Score and Tumor Proportion Score for Immunotherapy Response in Advanced NSCLC
2023 · Ezgi B. Ulas, Sayed M.S. Hashemi, et al. · JTO Clinical and Research Reports · 41
PDF
Single-arm trial of neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy in patients with resectable and borderline resectable lung cancer: the INCREASE study
2024 · Idris Bahce, Chris Dickhoff, et al. · Journal for ImmunoTherapy of Cancer · 21
PDF
Evaluating the significance of combining PD-L1 and TILs as biomarkers in non-small cell lung cancer patients treated with immunotherapy: a systematic review
2025 · Y. Derraze, S. M. S. Hashemi, et al. · BJC Reports · 11
Sex and Common Germline Variants Affect the Toxicity Profile and Pharmacokinetics of Alectinib: A Nationwide Cohort Study in Patients With ALK-Positive NSCLC
2024 · Niels Heersche, Daan A.C. Lanser, et al. · Journal of Thoracic Oncology · 9
PDF
950O Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable lung cancer: The INCREASE trial
2022 · I. Bahce, C. Dickhoff, et al. · Annals of Oncology · 9
The effect of tumor size and metastatic extent on the efficacy of first line pembrolizumab monotherapy in patients with high PD-L1 expressing advanced NSCLC tumors
2021 · Alexandra Schakenraad, Sayed Hashemi, et al. · Lung Cancer · 9
First exploration of the on-treatment changes in tumor and organ uptake of a radiolabeled anti PD-L1 antibody during chemoradiotherapy in patients with non-small cell lung cancer using whole body PET
2024 · Johanna E E Pouw, Sayed M S Hashemi, et al. · Journal for ImmunoTherapy of Cancer · 6
PDF
1851MO Pembrolizumab plus chemotherapy (PEM + CT) versus pembrolizumab (PEM) as first-line therapy for advanced NSCLC with PD-L1 tumor proportion score (TPS) ≥50%: Open-label, phase III, randomized trial (PAULIEN)
2025 · I. Houda, E.B. Ulas, et al. · Annals of Oncology · 5
Immune-modulating effects on tumor-draining lymph nodes of neoadjuvant chemoradiotherapy combined with dual immunotherapy in patients with T3-4N0-2 NSCLC
2025 · Ezgi B Ulas, Sofie J I Koomen, et al. · Journal for ImmunoTherapy of Cancer · 4
1445P A randomized phase III trial on Pembrolizumab Alone versUs pembrolizumab-chemotherapy in first LInE NSCLC (PAULIEN), results of the interim analysis
2023 · I. Houda, E.B. Ulas, et al. · Annals of Oncology · 3
PDF
Neoadjuvant immunochemotherapy in resectable non-small cell lung cancer: the more cycles, the better?
2023 · Ezgi B. Ulas, Idris Bahce · Translational Lung Cancer Research · 2
PDF
Rescue by radiotherapy and anti-CTLA4/PD-1 after failure of anti-PD-1 therapy in patients with metastatic NSCLC: the phase II RECLAIM trial
2026 · Ezgi B Ulas, Nora D Purcell, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
Baseline expression levels of drug metabolizing enzymes in non-small cell lung cancer biopsies show promising biomarker and target potential for long-term response to pembrolizumab
2025 · Kirsten De Ridder, Chiara Maria Vinchesi, et al. · medRxiv · 1
PDF
Survival outcomes with carboplatin versus cisplatin and the impact of COVID-19 on platinum choice: A nationwide Netherlands registry study in small cell lung cancer patients (CACIS)
2025 · Ilias Houda, Dwayne Naves, et al. · European Journal of Cancer · 1
PDF
62P Predictive value of combined positive score (CPS) and tumor proportion score (TPS) for immunotherapy response in advanced non-small cell lung cancer (NSCLC)
2023 · E.B. Ulas, S. Hashemi, et al. · Journal of Thoracic Oncology · 1
PDF
1020P Rescue by radiotherapy and anti-CTLA4/PD-1 after failure of anti-PD-1 therapy in metastatic NSCLC patients: The RECLAIM study
2022 · I. Bahce, F.L. Schneiders, et al. · Annals of Oncology · 1
Sex Impacts Progression-Free Survival of Alectinib through Drug Exposure in Patients with ALK- Positive Non-Small Cell Lung Cancer
2026 · Daan A.C. Lanser, Niels Heersche, et al. · 癌症：英文版
PDF
P3.13.16 Survival Outcomes With Carboplatin Versus Cisplatin and the Impact of COVID-19 on Platinum Choice in SCLC in the Netherlands
2025 · I. Houda, D. Naves, et al. · Journal of Thoracic Oncology
PT2.11.02 Rescue by Radiotherapy and Anti-CTLA4/PD-1 After Failure of Anti-PD-1 Therapy in Metastatic NSCLC Patients: the RECLAIM study
2025 · E.B. Ulas, F.L. Schneiders, et al. · Journal of Thoracic Oncology
1983P Does sex matter? Real-world progression-free survival of patients treated with alectinib for ALK+ mNSCLC
2025 · D. Lanser, N. Heersche, et al. · Annals of Oncology
The role of perioperative chemoimmunotherapy in resectable non-small cell lung cancer: insights from the NADIM trial
2025 · Amira de Koning, Ilias Houda, et al. · Translational Lung Cancer Research
1281P Impact of common germline variants on the toxicity profile and pharmacokinetics of alectinib
2024 · N. Heersche, D.A.C. Lanser, et al. · Annals of Oncology
PDF
1472: GeoMX spatial transcriptomics of TDLN after chemoradiotherapy and ICI in T3-4N0-1 NSCLC patients
2024 · Sofie Koomen, Ezgi B. Ulas, et al. · Radiotherapy and Oncology
Works count: 26
Citation count: 339
H-index: 8
I10-index: 5
Year
Topic
Type